Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New Data From Boehringer Ingelheim's Ongoing Linagliptin Trial Programme Show Promising Safety And Efficacy Results
Study results presented for the first

Elderly Persons Living With A Spouse Report Better Preventive Care Use Than Those Living Alone Or With Children
Elderly persons living with a spouse have more timely preventive service use than those living alone or with offspring. The sole exception is in the case of hypertension screening.
News of the day
Blogs Comment On Planned Parenthood Ad Campaign, Sex-Selective Abortion, Other Topics
The following summarizes selected women"s health-related blog entries.~ "A Radical Notion: Women"s Health Care as Mainstream," Cecile Richards, Huffington Post blogs: "To hammer ... home" the message that "Planned Parenthood and other essential community providers are the affordable, local access to basic preventive care that saves lives," the Planned Parenthood Action Center has introduced advertisements "educating the policy folks involved in fixing our health care system" about "why women"s health care needs to be taken care of in this mega-reform effort," Richards writes. She writes, "From cancer screenings to contraception to immunizations, the majority of women who go to women"s health care centers consider them their primary health care provider," adding, "In fact, more than 90% of what Planned Parenthood health centers do is preventive and primary care." According to Richards, "Essential community providers, including those who provide women"s health care, need to be part of any newly established health care system." She adds that "the three million patients who came to Planned Parenthood health centers last year can testify to it." Richards writes that "[f]amily planning and reproductive health care are unfortunately still not fully part of mainstream health care, even though 98% of women use contraception at some point in their lives -- there"s nothing more universal!" The "fact that women reproduce and, therefore, have different types of health care needs makes some folks on Capitol Hill go pale and start to sweat," Richards writes. She concludes, "Maybe one day we won"t need a special campaign to support women"s health," but "until then, Planned Parenthood is here to make sure women aren"t worse off after health care reform than before" (Richards, Huffington Post blogs, 6/18).~ "The Role of Medical Education in Preserving Abortion Access," Our Bodies, Our Blog: In response to a recent Salon opinion piece that examined whether there will be a next generation of abortion providers, the blog post discusses a few organizations that are "working to increase access to (accurate) abortion-related training." The blog includes links to Medical Students for Choice -- a group that "does student organizing and advocacy to influence medical school curricula, workshops ... and lectures on abortion techniques" -- and The Ryan Program -- which offers "funding, technical expertise, curriculum, workshops and other res to support training opportunities in abortion and contraception for ob-gyn residents." The blog entry also highlights the work of Physicians for Reproductive Choice and Health, which partners with members of the American Medical Student Association "to provide "project in a box" materials for medical students wanting to access and influence their schools" curricula on sexual and reproductive health" (Our Bodies, Our Blog, 6/18). ~ "Regulating Abortion May Be OK But Not To Avoid Sex-Selection," Marianne Mollmann, Huffington Post blogs: "Sex-selective abortion raises a multitude of overlapping ethical concerns regarding eugenics, population control and provider privilege or knowledge," according to Mollmann, advocacy director for the Human Rights Watch"s Women"s Rights Division. Mollmann writes that recent media reports indicating that sex-selective abortion occurs among some ethnic communities in the U.S. "has generated new discussion about what to do -- indeed what to think -- about the practice here." She continues that the "effect of abortion regulations depends on the context and motivation," adding that "[f]rom a human rights perspective, the regulation of medical procedures and interventions is legitimate and indeed often necessary so long as they are based on full respect for the full range of human rights." It is "perhaps tempting to hope that banning sex-selective abortions would safeguard the gender balance of future generations," but the "criminalization of abortion for whatever reason has in the past led only to underground and unsafe prac
Nutrition

FDA Appointed Arthritis Advisory Committee Recommends U.S. Food And Drug Administration Approval For KRYSTEXXA(TM) For Refractory Chronic Gout

Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced that the Arthritis Advisory Committee appointed by the U.S. Food and Drug Administration (FDA) recommended by a vote of 14 to 1 that KRYSTEXXA(TM) (pegloticase), a biologic PEGylated uricase enzyme, be granted marketing approval by the FDA for the treatment of refractory chronic gout. Refractory chronic gout or treatment failure gout (TFG) is gout in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with conventional urate-lowering therapy at the maximum medically appropriate dose or for whom conventional urate-lowering therapy is contraindicated. The current target Prescription Drug User Fee (PDUFA) action date for the FDA"s decision as to whether to grant marketing approval for KRYSTEXXA is August 1, 2009. "We are very pleased with the Advisory Committee"s recommendation, which supports our belief that KRYSTEXXA has a favorable risk to benefit profile in patients suffering from TFG," said Paul Hamelin, President of Savient Pharmaceuticals, Inc. "KRYSTEXXA has the potential to provide an important new treatment option for patients with TFG, who currently have no other available treatment options, and many of whom suffer from serious pain and disability." The Advisory Committee"s recommendation, although not binding, will be considered by the FDA in its review of the Biologics License Application that Savient has submitted for KRYSTEXXA. ABOUT SAVIENT PHARMACEUTICALS, INC. Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and marketing pharmaceutical products that target unmet medical needs in both niche and broader specialty markets. Savient is currently developing one product: KRYSTEXXA(TM) (pegloticase) as a therapy for patients with treatment failure gout, to control hyperuricemia and to manage the signs and symptoms of gout. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA, formerly referred to as Puricase(R), from Duke University and Mountain View Pharmaceuticals, Inc. Savient also manufactures and supplies Oxandrin(R) (oxandrolone tablets, USP) CIII in the U.S. FORWARD LOOKING LANGUAGE All statements other than statements of historical facts included in this press release are forward-looking statements that are subject to certain risks, trends and uncertainties that could cause actual results and achievements to differ materially from those expressed in such statements. These risks, trends and uncertainties are in some instances beyond our control. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions help identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding the efficacy and safety of KRYSTEXXA(TM) (pegloticase), our BLA filing with the FDA, the Advisory Committee, approval of the BLA, preparation for commercialization of KRYSTEXXA, and the market for KRYSTEXXA, are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on our assessment and interpretation of the currently available data and information, our Phase 3 clinical data and on current expectations, assumptions, estimates and projections about our business and the biopharmaceutical and specialty pharmaceutical industries in which we operate. Important factors that may affect our ability to achieve the matters addressed in these forward-looking statements include, but are not limited to, the possibility that the FDA may not approve our BLA for KRYSTEXXA, notwithstanding the recommendation of the Advisory Committee; any delay or failure by us in completing the development of KRYSTEXXA; varying interpretations of our clinical and CMC data by the FDA; difficulties in obtaining financing; potential development of alternative or more effective products by competitors; reliance on third parties to manufacture, market and distribute many of our products; economic, political and other risks associated with foreign operations; risks of maintaining protection for our intellectual property; risks of an adverse determination in intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical industry and other important factors set forth more fully in our reports filed with the Securities and Exchange Commission, to which investors are referred for further information. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements, which speak only as of the date of publication of this press release to shareholders. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make. We do not have a policy of updating or revising forward-looking statements and, except as required by law, assume no obligation to update any forward-looking statements. Savient Pharmaceuticals, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009